MX2018013630A - Composicion veterinaria de imidacloprid, moxidectina y praziquantel de administracion topica cutanea (spot on) para tratamiento y prevencion de las ecto y endoparasitosis que afectan a los perros. - Google Patents

Composicion veterinaria de imidacloprid, moxidectina y praziquantel de administracion topica cutanea (spot on) para tratamiento y prevencion de las ecto y endoparasitosis que afectan a los perros.

Info

Publication number
MX2018013630A
MX2018013630A MX2018013630A MX2018013630A MX2018013630A MX 2018013630 A MX2018013630 A MX 2018013630A MX 2018013630 A MX2018013630 A MX 2018013630A MX 2018013630 A MX2018013630 A MX 2018013630A MX 2018013630 A MX2018013630 A MX 2018013630A
Authority
MX
Mexico
Prior art keywords
praziquantel
moxidectin
imidacloprid
spot
endoparasitoses
Prior art date
Application number
MX2018013630A
Other languages
English (en)
Inventor
D Corrales Carlos
A Dale Jorge
Original Assignee
Labyes Usa Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labyes Usa Llc filed Critical Labyes Usa Llc
Publication of MX2018013630A publication Critical patent/MX2018013630A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

U n a c o mp o s i c i ó n v e t e r i n a r i a mo n o d o s i s d e a p l i c a c i ó n t ó p i c a ( s p o t - o n ) p a r a c a n e s q u e c o mp r e n d e : ( a ) I mi d a c l o p r i d , e n t r e 8 , 1 8 y 1 0 , 0 0 %; ( b ) Mo x i d e c t i n a , e n t r e 2 , 8 6 y 3 , 5 0 %; 5 ( c ) P r a z i q u a n t e l , e n t r e 8 , 1 8 y 1 0 , 0 0 %; y ( d ) u n s o l v e n t e a p r ó t i c o s e l e c c i o n a d o d e D ime t i l s u l f ó x i d o ( DMS O ) , N , N - d ime t i l a c e t a mi d a ( DMA C ) , N , N - d ime t i l f o rma mi d a ( DMF ) , y s u s me z c l a s , e n t r e 6 5 , 4 5 y 8 0 , 0 0 %; j u n t o c o n e x c i p i e n t e s v e t e r i n a r i a me n t e a c e p t a b l e s , y e n d o n d e l o s 10 p o r c e n t a j e s e s t á n r e f e r i d o s a l p e s o t o t a l d e l a c o mp o s i c i ó n . U s o d e u n a c a n t i d a d e f e c t i v a d e : ( a ) I mi d a c l o p r i d , ( b ) Mo x i d e c t i n a ; ( c ) P r a z i q u a n t e l ; y ( d ) u n s o l v e n t e a p r ó t i c o s e l e c c i o n a d o d e D ime t i l s u l f ó x i d o ( DMS O ) , N , N - d ime t i l a c e t a mi d a ( DMA C ) , N , N - d ime t i l f o rma mi d a ( DMF ) y s u s me z c l a s , j u n t o c o n e x c i p i e n t e s 15 v e t e r i n a r i a me n t e a c e p t a b l e s , p a r a l a p r e p a r a c i ó n d e u n a c o mp o s i c i ó n v e t e r i n a r i a mo n o d o s i s p a r a e l t r a t a mi e n t o , c o n t r o l y p r e v e n c i ó n d e l a s e c t o y e n d o p a r a s i t o s i s d e c a n e s , e n d o n d e d i c h a c o mp o s i c i ó n v e t e r i n a r i a e s t á a d a p t a d a p a r a s e r a d mi n i s t r a d a t ó p i c a me n t e ( s p o t - o n ) .
MX2018013630A 2016-05-18 2017-05-16 Composicion veterinaria de imidacloprid, moxidectina y praziquantel de administracion topica cutanea (spot on) para tratamiento y prevencion de las ecto y endoparasitosis que afectan a los perros. MX2018013630A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP160101448A AR104691A1 (es) 2016-05-18 2016-05-18 Composición veterinaria de imidacloprid, moxidectina y praziquantel de administración tópica cutánea (spot on) para tratamiento y prevención de las ecto y endoparasitosis que afectan a los perros
PCT/US2017/032851 WO2017201010A1 (en) 2016-05-18 2017-05-16 Veterinary composition comprising imidacloprid, moxidectin and praziquantel for cutaneous topical application (spot on), for the treatment and prevention of ecto and endoparasitoses affecting dogs

Publications (1)

Publication Number Publication Date
MX2018013630A true MX2018013630A (es) 2019-06-17

Family

ID=59714807

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013630A MX2018013630A (es) 2016-05-18 2017-05-16 Composicion veterinaria de imidacloprid, moxidectina y praziquantel de administracion topica cutanea (spot on) para tratamiento y prevencion de las ecto y endoparasitosis que afectan a los perros.

Country Status (9)

Country Link
US (1) US10695331B2 (es)
EP (1) EP3458051B1 (es)
JP (2) JP2019516793A (es)
CN (3) CN115737649A (es)
AR (1) AR104691A1 (es)
BR (1) BR112018073613A2 (es)
ES (1) ES2954856T3 (es)
MX (1) MX2018013630A (es)
WO (1) WO2017201010A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220054319A (ko) * 2019-08-14 2022-05-02 비토퀴놀 에스에이 기생충 방제용 티골라너를 포함하는 조성물
CN110772509A (zh) * 2019-10-17 2020-02-11 广东省农业科学院动物卫生研究所 一种吡虫啉与莫昔克丁二元醇质体及其制备方法和应用
EP3815677B1 (en) 2019-10-30 2023-08-30 KRKA, d.d., Novo mesto Stable veterinary composition comprising moxidectin and imidacloprid
CN114259464B (zh) * 2021-11-25 2022-11-22 吉林大学 一种复方莫昔克丁外用滴剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447414A (en) * 1982-12-21 1984-05-08 Cutter Laboratories, Inc. Carnivore anthelmintics
JPS6058914A (ja) * 1983-09-12 1985-04-05 Shionogi & Co Ltd イミダゾ−ル系抗真菌性外用ゲル製剤
MXPA05010659A (es) * 2003-04-04 2005-12-12 Merial Ltd Formulaciones veterinarias antihelminticas topicas.
CN101801188A (zh) 2007-07-12 2010-08-11 特拉加拉医药品公司 治疗癌症、肿瘤和肿瘤相关性疾病的方法和组合物
CN101854926A (zh) * 2007-07-31 2010-10-06 惠氏有限责任公司 局部用杀体内寄生虫组合物
GB0905365D0 (en) * 2009-03-27 2009-05-13 Norbrook Lab Ltd A topical parasiticide composition
CN101933929A (zh) * 2009-07-02 2011-01-05 天津瑞普生物技术股份有限公司 一种驱除犬、猫体内外寄生虫的复方制剂及其制备方法
US8980896B2 (en) * 2009-12-17 2015-03-17 Merial, Inc. Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles
JO3626B1 (ar) 2012-02-23 2020-08-27 Merial Inc تركيبات موضعية تحتوي على فيبرونيل و بيرميثرين و طرق استخدامها
ES2710921T3 (es) * 2012-09-19 2019-04-29 Microvascular Tissues Inc Composiciones para tratar y prevenir lesión y enfermedad tisular
AU2015292212B2 (en) * 2014-07-25 2019-03-14 Laurent Pharmaceuticals Solid oral formulation of fenretinide

Also Published As

Publication number Publication date
JP2019516793A (ja) 2019-06-20
ES2954856T3 (es) 2023-11-27
EP3458051A1 (en) 2019-03-27
EP3458051C0 (en) 2023-06-07
EP3458051A4 (en) 2020-01-08
EP3458051B1 (en) 2023-06-07
US20190070158A1 (en) 2019-03-07
JP7255043B2 (ja) 2023-04-11
CN108883092A (zh) 2018-11-23
WO2017201010A1 (en) 2017-11-23
AR104691A1 (es) 2017-08-09
JP2022052770A (ja) 2022-04-04
CN115645412A (zh) 2023-01-31
US10695331B2 (en) 2020-06-30
BR112018073613A2 (pt) 2019-02-26
CN115737649A (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
MX2018013630A (es) Composicion veterinaria de imidacloprid, moxidectina y praziquantel de administracion topica cutanea (spot on) para tratamiento y prevencion de las ecto y endoparasitosis que afectan a los perros.
BR112020015688A8 (pt) Formulações tópicas que compreendem tofacitinibe
CL2004000234A1 (es) Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
MY187047A (en) Selective pyy compounds and uses thereof
NZ611476A (en) Topical localized isoxazoline formulation
BR112014019262A8 (pt) Composições orais veterinárias parasíticas compreendendo ingredientes ativos de ação sistêmica, métodos e uso das mesmas
JP2008542271A5 (es)
BR112015018033A2 (pt) Composto, composição farmacêutica, e, uso de um composto
UY36373A (es) Compuestos para usarse en el tratamiento antihelmíntico
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
BR112016016732A8 (pt) derivados de benzimidazol, seus usos, e composições farmacêuticas para tratamento de distúrbios inflamatórios
MX2019014935A (es) Antagonistas muscarinicos y sus combinaciones para el tratamiento de enfermedades de las vias respiratorias en caballos.
WO2017220042A3 (zh) 氨力农的药物组合物及其在高血压治疗中的应用
MX2019011620A (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
WO2016048861A3 (en) Heterocyclic compounds and use thereof
NZ701697A (en) Stable veterinary anthelmintic formulations
PE20151726A1 (es) Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles
UY37907A (es) 3-fenilquinazolin-4 (3h)-onas sustituidas y sus usos
BR112014025017A2 (pt) Composição farmacêutica injetável antibacteriana
JIN et al. Effects of ambient ozone on human respiratory system
CL2016000724A1 (es) Acido {4-[5-(3-cloro-fenoxi)-oxazolo[5,4-d]pirimidin-2-il]-2,6-dimetil-fenoxi}acetico para su uso e n la prevencion o el tratamiento de la lesion renal aguda.
HRP20211558T1 (hr) Formulacija
HRP20170897A2 (hr) Topikalna farmaceutska formulacija na bazi mupirocina kao antivirusno sredstvo
NZ594610A (en) Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants